VNDA Vanda Pharmaceuticals Inc

Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares rise nearly 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the near-flat price range of $2.44 to $2.67 in the past one-month time frame.

In the past 30 days, there have been no estimate revisions but the company’s Zacks Consensus Estimate moved lower, suggesting trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Agenus currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Some other stocks worth considering in the Med-Biomed sector include Heska Corporation (HSKA), Vanda Pharmaceuticals, Inc. (VNDA) and Achillion Pharmaceuticals, Inc. (ACHN). While Heksa and Vanda hold a Zacks Rank #1 (Strong Buy), Achillion carries a Zacks Rank #2.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
 
ACHILLION PHARM (ACHN): Free Stock Analysis Report
 
AGENUS INC (AGEN): Free Stock Analysis Report
 
HESKA CORP (HSKA): Free Stock Analysis Report
 
VANDA PHARMACT (VNDA): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research